trial

A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

NCTId NCT06821945
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 120 (estimated)
Sponsored by Boryung Pharmaceutical Co., Ltd
Primary completion 2027-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2025-05-30
Primary completion
2027-05
Eligibility
ALL · 19 Years

Interventions & indications

Drugs
BR5402ABR5402A-1BR5402BBR5402B-1BR5402CBR5402C-1BR5402DBR5402D-1

Sponsors

Boryung Pharmaceutical Co., LtdLead Sponsor

Sites

2 total
Daegu, South KoreaGuri-si, South Korea

Linked catalysts

1
A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Sch — primary completion2027-05

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE2
Primary Completion Date
2027-05
Status
RECRUITING
relationships
The graph out of here
drug
BR5402A
drug
BR5402A-1
drug
BR5402B
drug
BR5402B-1
drug
BR5402C
drug
BR5402C-1
drug
BR5402D
drug
BR5402D-1
drug
lead_sponsor
Boryung Pharmaceutical Co., Ltd
company
indication
Schizophrenia
indication
Schizophrenia
indication